Proveca receives positive CHMP opinion for additional 1 mg strength of Bopediat® (furosemide) orodispersible tablets, a step towards expanding treatment options for children with oedema
This press release is intended for investors only
Proveca receives positive CHMP opinion for additional 1 mg strength of Bopediat® (furosemide) orodispersible tablets, a step towards expanding treatment options for children with oedema
Proveca is delighted to announce that on the 12th November 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Bopediat® (furosemide) 1 mg orodispersible tablets, intended for prescription-only use (marketing authorisation pending), as an additional strength under the existing Paediatric Use Marketing Authorisation (PUMA).
Bopediat® is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.
Following the European Commission (EC) approval of Bopediat 5 mg orodispersible tablets, announced in June 2026, Proveca is delighted to announce this further positive regulatory milestone for the additional 1 mg strength. The positive CHMP opinion will now be considered by the EC, which is responsible for the final decision on extending the marketing authorisation. A decision is anticipated by January 2027.
Dr Simon Bryson, CEO, Proveca – “The authorisation of Bopediat® earlier this year represented an important milestone for Proveca, becoming our third PUMA. The positive CHMP opinion for the additional 1 mg orodispersible tablet strength represents further progress in our commitment to developing age-appropriate medicines for children. I am proud of the Proveca team and their continued contribution to approval of five of the ten PUMAs granted to date, reflecting the company’s expertise and commitment to addressing unmet needs in paediatric healthcare.”
Dr Harry Smith, Chief Medical Officer, Proveca – “Paediatric prescribing often requires treatment to be carefully tailored to the individual child. The additional 1 mg strength of Bopediat® provides greater flexibility in furosemide dosing, while its orodispersible formulation offers an important alternative for children who have difficulty swallowing conventional tablets.”
About Oedema and Hypertension in Children and Adolescence
Oedema refers to the accumulation of excess fluid in the body’s tissues and may occur in paediatric patients from birth through to adolescence as a result of cardiac, renal or hepatic conditions. The clinical presentation and severity of oedema in children vary depending on the underlying cause and disease progression.
Hypertension in paediatric patients is defined as persistently elevated blood pressure relative to age, sex and height. Although less common than in the adult population, paediatric hypertension is well recognised and requires appropriate clinical management to reduce long-term complications. The availability of child-appropriate formulations is an important consideration in paediatric care, as administration challenges may impact treatment outcomes in younger populations.
About Bopediat®
Bopediat® is an orodispersible tablet which contains the active pharmaceutical ingredient, furosemide (a loop diuretic). The tablet strengths are 5 mg and 1 mg and include a functional score line, enabling accurate doses of 2.5 mg and 0.5 mg respectively. Furosemide is a widely used diuretic with a well understood safety profile; very common adverse reactions (≥1/10) include: electrolyte imbalance, dehydration, hypovolaemia, increase in serum creatinine, increase in triglycerides and orthostatic hypotension.
About Proveca
Proveca is a UK-founded pharmaceutical company, with technical and commercial operations globally. The company specialises in the development, licensing and commercialisation of evidence-based medicines to address the unmet medical needs of children, with a current paediatric product portfolio in neurology and cardiology.
For more information about Proveca and/or this press release, please contact:
Dr Simon Bryson, CEO
Phone: +44 161 468 2627
Email: medical@proveca.com
www.proveca.com
INT-FUR-26-0003, Nov 2026
